Clofazimine as a substitute for rifampicin improves efficacy of <i>Mycobacterium avium</i> pulmonary disease treatment in the hollow-fiber model.

ABSTRACT: Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine. Intrapulmonary pharmacokinetic profiles of azithromycin, ethambutol, and rifampicin were simulated. For clofazimine, a steady-state average concentration was targeted. Drug concent

SUBMITTER: Salillas S 

PROVIDER: S-EPMC10916390 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature